医学
心力衰竭
重症监护医学
肾脏疾病
高钾血症
肾功能
糖尿病
内科学
心脏病学
内分泌学
作者
Michele Senni,Edoardo Sciatti,Elisabetta Bussalino,Emilia D’Elia,Maura Ravera,Ernesto Paoletti
出处
期刊:Journal of Cardiovascular Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2023-08-30
卷期号:24 (11): 781-789
标识
DOI:10.2459/jcm.0000000000001555
摘要
Hyperkalaemia is a life-threatening condition leading to significant morbidity and mortality. It is common in heart failure and in chronic kidney disease (CKD) patients due to the diseases themselves, which often coexist, the high co-presence of diabetes, the fluctuations in renal function, and the use of some drugs [i.e. renin-angiotensin-aldosterone system (RAAS) inhibitors]. Hyperkalaemia limits their administration or uptitration, thus impacting on mortality. New K + binders, namely patiromer and sodium zirconium cyclosilicate (ZS-9), are an intriguing option to manage hyperkalaemia in heart failure and/or CKD patients, both to reduce its fatal effects and to let clinicians uptitrate RAAS inhibition. Even if their real impact on strong outcomes is still to be determined, we hereby provide a practical approach to favour their use in routine clinical practice in order to gain the correct confidence and provide an additive tool to heart failure and CKD patients' wellbeing. New trials are welcome to fill the gap in knowledge.
科研通智能强力驱动
Strongly Powered by AbleSci AI